Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing hosts

Cellular and Molecular Immunology

Volumn 7, Issue 4, 2010, Pages 306-315

  Bhattacharyya, Sankar ^a   Md Sakib Hossain, Dewan ^a   Mohanty, Suchismita ^a   Sankar Sen, Gouri ^a   Chattopadhyay, Sreya ^a   Banerjee, Shuvomoy ^a   Chakraborty, Juni ^a   Das, Kaushik ^a   Sarkar, Diptendra ^a   Das, Tanya ^a   Sa, Gaurisankar ^a  

^a BOSE INSTITUTE   (India)

Author keywords

CD4+ CD8+ T cell; Effector T cell; FoxP3; T regulatory cell; Th1 Th2

Indexed keywords

CURCUMIN; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA; ANTINEOPLASTIC AGENT; CD4 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; INTERLEUKIN 2 RECEPTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CELL LOSS; CELLULAR IMMUNODEFICIENCY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; EHRLICH ASCITES TUMOR; IMMUNE RESPONSE; IMMUNOREGULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR VOLUME; ANIMAL; CELL PROLIFERATION; CYTOLOGY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG SCREENING; HELPER CELL; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; NEOPLASM; PATHOLOGY; SURVIVAL; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, CD4; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CURCUMIN; CYTOTOXICITY, IMMUNOLOGIC; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOLOGIC MEMORY; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE DEPLETION; MICE; NEOPLASMS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 77957266536     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2010.11     Document Type: Article

References (47)

1. Ohm JE, Carbone DP. Immune dysfunction in cancer patients. Oncology 2002; 16: 11-18.
2. Kandil A, Bazarbashi S, Mourad WA. The correlation of Epstein-Barr virus expression and lymphocyte subsets with the clinical presentation of nodular sclerosing Hodgkin disease. Cancer 2001; 91: 1957-1963. (Pubitemid 32476358)
3. Alexander JP, Kudoh S, Melsop KA, Hamilton TA, Edinger MG, Tubbs RP et al. T cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors. Cancer Res 1993; 53: 1380-1387. (Pubitemid 23097120)
4. Shanker A, Singh SM, Sodhi A. Ascitic growth of a spontaneous transplantable T cell lymphoma induces thymic involution. 1. Alterations in the CD4/CD8 distribution in thymocytes. Tumour Biol 2000; 21: 288-298. (Pubitemid 30666033)
5. Das T, Sa G, Paszkiewicz-Kozik E, Hilston C, Molto L, Rayman P et al. Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptor-independent pathways. J Immunol 2008; 180: 4687-4696.
6. Gastman BR, Johnson DE, Whiteside TL, Rabinowich H. Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 2000; 95: 2015-2023. (Pubitemid 30151640)
7. Sa G, Das T, Moon C, Hilston CM, Rayman PA, Rini BI et al. GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res 2009; 69: 3095-3104.
8. Das T, Sa G, Hilston C, Kudo D, Rayman P, Biswas K et al. GM1 and TNFa, overexpressed in renal cell carcinoma, synergize to induce T cell apoptosis. Cancer Res 2008; 68: 2014-2023. (Pubitemid 351416589)
9. Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S et al. Selective cytokine gene expression in renal cell carcinoma tumor cells and tumor-infiltrating lymphocytes. Int J Cancer 1995; 61: 780-785.
10. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G et al. Regulatory CD41CD251 T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61: 4766-4772. (Pubitemid 32691889)
11. Cao Q, Wang L, Du F, Sheng H, Zhang Y, Wu J et al. Downregulation of CD41CD251 regulatory T cells may underlie enhanced Th1 immunity caused by immunization with activated autologous T cells. Cell Res 2007; 17: 627-637. (Pubitemid 47116358)
12. Parmiani G, Rivoltini L, Andreola G, Carrabba M. Cytokines in cancer therapy. Immunol Lett 2000; 74: 41-44.
13. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ et al. IFNc and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-1111. (Pubitemid 32391043)
14. Kemp RA, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001; 167: 6497-6502. (Pubitemid 33081584)
15. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189: 753-756. (Pubitemid 29189679)
16. Tatsumi T, Herrem CJ, Olson WC, Finke JH, Bukowski RM, Kinch MS et al. Disease stage variation in CD41 and CD81 T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003; 63: 4481-4489. (Pubitemid 36951020)
17. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of tumor escapé́ phenotypes. Nat Immunol 2002; 3: 999-1005. (Pubitemid 35363649)
18. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from Tcell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
19. Sakaguchi S, Sakaguchi N, Asano M, Itoh M. Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
20. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV et al. Blocking angiotensinconverting enzyme induces potent regulatory T cells and modulates TH1- and TH17- mediated autoimmunity. Proc Natl Acad Sci USA 2009;106: 14948-14953.
21. Neujahr DC, Cardona AC, Ulukpo O, Rigby M, Pelaez A, Ramirez A et al. Dynamics of human regulatory T cells in lung lavages of lung transplant recipients. Transplantation 2009; 88: 521-527.
22. Haas M, Dimmler A, Hohenberger W, Grabenbauer GG, Niedobitek G, Distel LV. Stromal regulatory T-cells are associated with a favorable prognosis in gastric cancer of the cardia. BMC Gastroenterol 2009; 9: 65.
23. Marshall NA, Christie LE, Munro LR, Culligan DJ, Johnston PW, Barker RN et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103: 1755-1762. (Pubitemid 38268969)
24. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-1174. (Pubitemid 46718401)
25. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor a) monoclonal antibody. Cancer Res 1999; 59: 3128-3133. (Pubitemid 29316012)
26. Sasada T, Kimura M, Yoshida Y, Kanai M, Takabayashi A. CD41CD251 regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression. Cancer Res 2003; 98: 1089-1099. (Pubitemid 37022112)
27. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949. (Pubitemid 39273735)
28. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1-expressed cells at G2 phase of cell cycle in a p53-dependent manner. J Biol Chem 2005; 280: 20059-20068. (Pubitemid 41379535)
29. Bhattacharyya S, Mandal D, Sen GS, Pal S, Banerjee S, Lahiry L et al. Tumor-induced oxidative stress perturbs nuclear factor-kB activity-augmenting tumor necrosis factor-a-mediated T-cell death: protection by curcumin. Cancer Res 2007; 67: 362-370. (Pubitemid 46142796)
30. Bhattacharyya S, Mandal D, Saha B, Sen GS, Das T, Sa G. Curcumin prevents tumorinduced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 2007; 282: 15954-15964. (Pubitemid 47100378)
31. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-763. (Pubitemid 38680440)
32. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189: 753-756. (Pubitemid 29189679)
33. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD41CD251 regulatory T cells is mediated by cell surface-bound transforming growth factor b. J Exp Med 2001; 194: 629-644. (Pubitemid 32844773)
34. Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M. Melanoma induces immunosuppression by up-regulating FOXP31 regulatory T cells. J Surg Res 2007; 141: 72-77. (Pubitemid 46898447)
35. Chen X, Subleski JJ, Kopf H, Howard OM, Männel DN, Oppenheim JJ. Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD41CD251FoxP31 T regulatory cells: applicability to tumor-infiltrating T regulatory cells. J Immunol 2008; 180: 6467-6471.
36. Sheu BC, Lin RH, Lien HC, Ho HN, Hsu SM, Huang SC. Predominant Th2/Tc2 polarity of tumor-infiltrating lymphocytes in human cervical cancer. J Immunol 2001; 167: 2972-2978.
37. Cao X. Regulatory T cells and immune tolerance to tumors. Immunol Res in press
38. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD41 T cells are required for secondary expansion and memory in CD81 T lymphocytes. Nature 2003; 421: 852-856. (Pubitemid 36254145)
39. Matsui S, Ahlers JD, Vortmeyer AO, Terabe M, Tsukui T, Carbone DP et al. A model for CD81 CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 1999; 163: 184-193. (Pubitemid 29295840)
40. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend or foe? Tissue Antigens 2007; 70: 1-11. (Pubitemid 46890289)
41. Vose BM, Moore M. Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol 1985; 22: 27-40.
42. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD41CD25hi Foxp31 regulatory T cells in cancer patients. Blood 2006; 107: 2409-2414. (Pubitemid 43345561)
43. Möbs C, Slotosch C, Löffler H, Pfutzner W, Hertl M. Cellular and humoral mechanisms of immune tolerance in immediate-type allergy induced by specific immunotherapy. Int Arch Allergy Immunol 2008; 147: 171-178.
44. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD41CD251Foxp31 regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD41 T cells. Nat Immunol 2007; 8: 1353-1362. (Pubitemid 350131172)
45. Kim JY, Kim KH, Lee SH. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kB as potential targets. J Immunol 2005; 174: 8116-8124.
46. Churchill M, Chadburn A, Bilinski RT, Bertagnolli MM. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. J Surg Res 2000; 89: 169-175. (Pubitemid 30196521)
47. Gertsch J, Guttinger M, Heilmann J, Sticher O. Curcumin differentially modulates mRNA profiles in Jurkat T and human peripheral blood mononuclear cells. Bioorg Med Chem 2003; 11: 1057-1063. (Pubitemid 36287067)